Philipp M Roessner

13PUBLICATIONS
59CO-AUTHORS
Molecular medicineMolecular targetsCheminformatics and quantitative structure-activity relationshipsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Dec 05, 2025
Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers.

Rolf Grempler, David Joseph, Guanfa Gan

|Oct 08, 2025
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.

Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi

|Dec 27, 2024
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers.

Xiaofan Tian, Habib Esmaeili, David Minich

|Apr 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

Philipp M Roessner, Isabelle Seufert, Vicente Chapaprieta

|Nov 17, 2021
Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?

Philipp M Roessner, Martina Seiffert

|Oct 18, 2021
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan

Pageof 3

Frequent Collaborators

7 joint publications

Martina Seiffert

4 joint publications

Tobias Roider

3 joint publications

Selcen Öztürk

3 joint publications

Sascha Dietrich